Pyxis Oncology, Inc. Proceeds from Issuance of Private Placement
Pyxis Oncology, Inc. (PYXS) reported Proceeds from Issuance of Private Placement of $10.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-13
- 2026-06-30: Proceeds from Issuance of Private Placement 6 month $10.00M.
- 2025-06-30: Proceeds from Issuance of Private Placement 6 month $0.00.
| Period end | Proceeds from Issuance of Private Placement 6 month |
|---|---|
| 2026-06-30 | $10.00M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |